Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
ID: 333357Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/333357

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-229.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants," aimed at promoting the screening, validation, and characterization of genetic variants associated with congenital defects. This initiative seeks to bridge the gap between identifying potential genetic variants and understanding their functional implications on phenotypes related to structural birth defects, intellectual disabilities, and metabolic disorders, utilizing advances in genetic technologies and publicly available genomic data. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and community-based organizations, with a maximum funding amount of $499,999 per year for a project period of up to five years. Interested parties should submit their applications by May 7, 2025, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further assistance.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-21-229-Full-Announcement.html
    PAR-21-229.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants." The initiative aims to promote the screening, validation, and characterization of genetic variants linked to congenital defects, utilizing advances in genetic technologies and publicly available genomic data. The funding is intended to bridge the gap between identifying potential genetic variants and understanding their functional implications on phenotypes related to structural birth defects, intellectual disabilities, and metabolic disorders. Applications are solicited for various study approaches, including non-hypothesis driven screening and hypothesis-driven mechanistic studies. Successful proposals will reflect innovative methodologies using available genomic databases, in vitro, and in vivo models. The maximum budget is $499,999 per year for a project period of up to five years, with an application process adhering strictly to NIH standards. Key dates include application due dates in June and February each year through 2025, emphasizing the importance of early submission to correct potential errors. The document details eligibility criteria, required registrations, and an extensive review process evaluating scientific merit, significance, approach, and investigator qualifications. Overall, this funding opportunity supports research aimed at understanding and improving interventions for birth defects through genomic insights.
    Similar Opportunities
    Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the screening and functional validation of genomic variants associated with human congenital anomalies through the R01 Clinical Trial Not Allowed grant. This initiative aims to leverage advancements in genomic technologies to identify and validate genetic variants linked to congenital defects, intellectual developmental disabilities, and inborn errors of metabolism, thereby bridging the gap between genetic identification and functional impact on health. Eligible applicants include a wide range of institutions such as universities, nonprofits, and tribal governments, with a maximum budget of $499,999 per project year and a project duration of up to five years. Interested parties should submit their applications by January 7, 2028, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-185.html for further details.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This initiative encourages applicants to utilize advancements in genetics, omics methods, and synthetic biology to explore genetic, environmental, and epigenetic factors contributing to these anomalies, which affect approximately 3% of live births in the U.S. The grant allows for budgets up to $499,999 in direct costs per year, with project periods not exceeding five years, and applications are due by February 5, 2025. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research into the natural history of disorders detectable through newborn screening, under the grant title "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)." This initiative aims to enhance understanding of these disorders to support early identification and intervention, focusing on improving diagnostic accuracy, elucidating genetic and clinical heterogeneity, and exploring underlying mechanisms to inform treatment options. The funding is available for new, renewal, resubmission, or revision applications, with a maximum support period of five years and no cost-sharing requirement. Interested applicants, including various educational and community organizations, must submit proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance or further information.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at advancing research in novel screening methods and therapeutic interventions for genetic conditions identified through newborn screening. This initiative encourages the development of innovative screening assays, the use of artificial intelligence, and the exploration of socio-economic implications related to newborn screening, with a focus on conditions that may benefit from early detection and treatment. The grant supports long-term research projects (R01) and is open to a diverse range of applicants, including higher education institutions and community-based organizations, with applications accepted until November 16, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.html.
    ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the opportunity titled "ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed)" to establish Expert Panels focused on the clinical relevance of genetic variants. The primary objective of this initiative is to develop a comprehensive knowledge base that enhances the interpretation of genes and genomic variants associated with high-priority diseases, utilizing established tools and resources from the Clinical Genomics Resource (ClinGen) and ClinVar. This funding is crucial for advancing genomic research and improving clinical outcomes through precision medicine, with a maximum award ceiling of $220,000 per year for a grant period of up to three years. Interested applicants must submit their proposals by May 25, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovation in the application of genomic information in clinical care, particularly for populations experiencing health disparities. The initiative seeks to enhance understanding of how to effectively implement and share genomic technologies across diverse communities, including racial and ethnic minorities, underserved rural populations, and sexual and gender minority groups. With an expected total funding of approximately $1.5 million for fiscal year 2024, individual project budgets may reach up to $250,000. Interested applicants must submit their proposals by February 11, 2025, and can find additional details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative encourages applications for small research projects that explore the integration of genomic data into clinical practice, assess barriers to implementation, and develop innovative data analysis techniques, particularly focusing on underrepresented populations in genomic research. The maximum budget for each application is $50,000 over a two-year period, with a total funding expectation of approximately $150,000 for FY 2024. Interested applicants must submit their proposals by February 12, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.